Tumor-suppressive and promoting function of transforming growth factor beta

被引:30
作者
Sun, LZ [1 ]
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA
关键词
TGF beta; cancer; tumor progression; antagonists; review;
D O I
10.2741/1382
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transforming growth factor beta (TGFbeta) is a multifunctional polypeptide. Its role in carcinogenesis can be either suppressive or promoting depending on tumor developmental stages and cellular context. During the early phase of epithelial tumorigenesis, TGFbeta inhibits primary tumor development and growth by inducing cell cycle arrest and possibly apoptosis. However, in late stages of progression, as tumor cells evade the growth inhibition by TGFbeta due to inactivation of its signaling pathway or aberrant regulation of cell cycle machinery, the role of TGFbeta signaling is often switched from tumor suppression to promotion. TGFbeta can apparently act in tumor stroma as well as tumor cells to inhibit host immune surveillance and stimulate invasion, angiogenesis, and metastasis. Studies have shown that antagonizing TGFbeta activity can inhibit tumor progression, especially metastasis, in certain tumor models. However, the molecular markers that can indicate the feasibility of the use of TGFbeta antagonists as cancer therapeutics remain to be determined.
引用
收藏
页码:1925 / 1935
页数:11
相关论文
共 123 条
[1]   The somatic mutation frequency of the transforming growth factor beta receptor type II gene varies widely among different cancers with microsatellite instability [J].
Abe, T ;
Hong, OY ;
Migita, T ;
Kato, Y ;
Kimura, M ;
Shiiba, K ;
Sunamura, M ;
Matsuno, S ;
Horii, A .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 1996, 22 (05) :474-477
[2]   Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development [J].
Amendt, C ;
Schirmacher, P ;
Weber, H ;
Blessing, M .
ONCOGENE, 1998, 17 (01) :25-34
[3]  
ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367
[4]   Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β [J].
Arteaga, CL ;
Koli, KM ;
Dugger, TC ;
Clarke, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (01) :46-53
[5]  
ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193
[6]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[7]  
Bandyopadhyay A, 1999, CANCER RES, V59, P5041
[8]  
Bandyopadhyay A, 2002, CANCER RES, V62, P4690
[9]   Extracellular domain of TGFβ type III receptor inhibits angiogenesis and tumor growth in human cancer cells [J].
Bandyopadhyay, A ;
Zhu, Y ;
Malik, SN ;
Kreisberg, J ;
Brattain, MG ;
Sprague, EA ;
Luo, J ;
López-Casillas, F ;
Sun, LZ .
ONCOGENE, 2002, 21 (22) :3541-3551
[10]   TRANSCRIPTS FOR TRANSFORMING GROWTH-FACTORS IN HUMAN BREAST-CANCER - CLINICAL CORRELATES [J].
BARRETTLEE, P ;
TRAVERS, M ;
LUQMANI, Y ;
COOMBES, RC .
BRITISH JOURNAL OF CANCER, 1990, 61 (04) :612-617